Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder | Zendy

Jing Tian | Zendy; Wenzhu Tang | Zendy; Ming Xu | Zendy; Chen Zhang | Zendy; Pei Zhao | Zendy; Tongtong Cao | Zendy; Xiaoli Shan | Zendy; Rong Lü | Zendy; Wei Guo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder

Author(s) -

Jing Tian,

Wenzhu Tang,

Ming Xu,

Chen Zhang,

Pei Zhao,

Tongtong Cao,

Xiaoli Shan,

Rong Lü,

Wei Guo

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000494791

Subject(s) - tfam , diabetic cardiomyopathy , medicine , endocrinology , ampk , amp activated protein kinase , carnitine , biology , mitochondrial biogenesis , mitochondrion , chemistry , protein kinase a , cardiomyopathy , phosphorylation , microbiology and biotechnology , heart failure

Shengmai San (SMS), prepared from Panax ginseng, Ophiopogon japonicus, and Schisandra chinensisin, has been widely used to treat ischemic disease. In this study, we investigated whether SMS may exert a beneficial effect in diabetic cardiomyopathy through improvement of mitochondrial lipid metabolism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research